Crowdonomics
All companies
KOIOS MEDICAL, INC logo

KOIOS MEDICAL, INC

Operating

Koios Medical, Inc.

Healthcare · New York, NY · Founded 2011

Visit website641 followers on WeFunder · as of Sep 30, 2026

AI-powered software diagnosing cancer. Super human accuracy

Post-money valuation ⓘ
$92.6M
As of Sep 2026 · from Reg CF Offering (2025) · pre-money + amount raised, not a traded price
Total raised
$14,939,836
Crowd $3.9M · Private $11.0M · 7 rounds since 2021
Latest share price
$4.6998
Reg CF · Preferred Stock · Dec 2025 offering price

Financials

FY2022–FY2025 · from SEC filings · hover any figure for its source
$50K
−$5.6M
2022
$293K
−$5.6M
2023
$637K
−$4.8M
2024
$1.6M
−$2.7M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 audited
FY2023 audited
FY2024 audited
FY2025 audited
Income statement
Revenue
$49,911
$293,350
$637,331
$1,620,593
Cost of goods sold
$189,738
$71,355
$267,049
$293,128
Gross margin
-280%
76%
58%
82%
Net income
-$5,600,235
-$5,571,268
-$4,761,652
-$2,687,228
Taxes paid
$5,228
$1,934
$0
$0
Balance sheet
Cash
$1,193,518
$2,123,822
$46,425
$168,058
Accounts receivable
$49,579
$31,750
$103,563
$322,821
Total assets
$1,466,393
$2,465,729
$369,719
$753,413
Short-term debt
$6,339,259
$934,027
$1,968,362
$1,766,418
Long-term debt
$0
$0
$0
$988,702
Total liabilities
$6,339,259
$934,027
$1,968,362
$2,755,120
Other
Headcount
—
20
17
12

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$60.0M
pre-money
$90.0M
pre-money
Reg CF · Preferred · Apr 2024
Reg CF · Preferred · Dec 2025

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$4.6998$2.3499$4.0108
Apr 2024Dec 2025
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Principal holders% as the filing states it, Apr 28, 2026

  • KMed Investments LC24.0%of company

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $2.6M / $2.6MInvestors 982Post-money $92.6M
Raised $1.3M / $500MInvestors 447Post-money $61.3M
Raised $170KInvestors 4
Raised $8MInvestors 1
Raised $2.6MInvestors 25
Raised $280KInvestors 7

Team

12 people
Chad McClennanFounder
President & CEO

Healthcare Visionary. Co-founded medical software company acquired by Stryker. 25+ years advising Fortune 500 clients including Humana. Ex-Arthur Andersen Senior Manager. Now leads Newsweek's 'World's Best Digital Health Company.' Northwestern MBA.

Ajit Jairaj
Vice President, R&D

AI Pioneer. Designed facial recognition systems for US DoD. Pivoted to medical imaging. Published X peer-reviewed medical imaging research. Oversees Koios R&D developing algorithms trained on 500,000+ ultrasound images

Bill Hulbert
Vice President, Software Development

AI Veteran. Designed enterprise facial recognition systems & commercial SDKs. Led Koios to HuffPost's '10 AI Health Companies to Follow.' 4-year varsity athlete (Captain). Rutgers University Engineering BS (Honors). DSP specialist.

Graham Anderson
Chief Financial & Administrative Officer

VC Veteran. Structured deals across healthcare IT, specialty pharmaceuticals & consumer products. Corporate board experience includes Audit, Compensation & Governance Committees. Corp dev, enterprise sales expertise. CFA Charterholder. Yale Law School JD.

Jon Robinson
Vice President, Software Product

Software Veteran. 20+ years designing & delivering radiology software. Director at Intelerad Medical Systems (acquired by GE HealthCare for $2.3B), serving 1,500+ healthcare organizations globally, including 41 of top 100 U.S. radiology groups.

Lev Barinov
Vice President Clinical Excellence

Diagnostic Innovator. Led research proving AI boosts cancer detection 14%, reduces false positives 35%. Multiple FDA clearances. UPenn and Memorial Sloan Kettering published research. Rutgers BS and MD; Princeton Quantitative Molecular Biology PhD.

Omar Partida
Chief Development Officer

Imaging Master. 20+ years at RadNet (largest U.S. outpatient imaging provider, 400+ centers). Launched PET/CT, PET/MR & Nuclear Medicine programs. Led largest international cancer-screening partnership in Middle East. UC San Diego Nuclear Medicine.

Peter Graham
Vice Presidents, Sales

Revenue Driver. 25+ years building top-performing sales and revenue growth teams. Focus on radiology and AI solutions for oncology and women’s health. Former SVP at iCAD. Led teams at Tempus, Volpara, Xoft. Clarkson University Mechanical Engineering BS.

Joanie Collins
Clinical Applications, Enablement & Engagement Specialist

Sonography Specialist. Registered Diagnostic Medical Sonographer/Ultrasound Technologist. Trained 100+ healthcare facilities to improve diagnostic accuracy in lesion categorization.

Show 3 more people
Robin Allman
Customer Enablement & Clinical Strategy Leader

Clinical Technologist. 20+ years at Vanderbilt Medical Center & Saint Thomas Health in breast imaging. Specialist at Perimeter Medical Imaging AI teaching optical coherence tomography to surgeons. RT(R)(M)(BS), ARRT certified.

Mark glasgold
Chairman
Gregory S. Moran
Director

Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Compliant

Filed 2 of 2 annual reports (FY2024–FY2025)

982 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C/ASep 28, 20260001764417-26-000009
    EDGAR
  • Form C/AAug 21, 20260001764417-26-000006
    EDGAR
  • Form C/AApr 29, 20260001764417-26-000004
    EDGAR
  • Form C-ARApr 28, 20260001764417-26-000002
    EDGAR
  • Form C/AJan 21, 20260001764417-26-000001
    EDGAR
  • Form DDec 23, 20250001764417-25-000003
    EDGAR
  • Form CDec 17, 20250001764417-25-000002
    EDGAR
  • Form C-ARApr 25, 20250001670254-25-000428
    EDGAR
Source: ManualCIK 0001764417Share price $4.6998

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.